Clinical Microbiology: Open Access

Biofilm formation and antimicrobial susceptibility of NT H. influenzae (NTHi) strains isolated from Mexican adults with COPD

8^th CLINICAL MICROBIOLOGY CONFERENCE

October 26-28, 2017 | Paris, France

Patricia Gomez de Leon

Universidad Nacional Autonoma de Mexico, Mexico

Posters & Accepted Abstracts: Clin Microbiol

Abstract:

NTHi is a cause of respiratory infections among adults with Chronic Obstructive Pulmonary Disease (COPD). Lines of evidence suggest that biofilm formation by NTHi play an important role in pathogenesis of COPD. Our objective was to assess the possible correlation between the antimicrobial susceptibility and the ability of NTHi to form biofilms. Forty NTHi strains from hospitalized adults with COPD (Mexico City) were evaluated for their biofilm formation ability by a crystal violet staining-based assay and optical density (OD) measurements. NTHi strains 2019 and siaB- mutant (E. Swords, USA) were included. The antimicrobial susceptibility patterns against nine antibiotics were determined by the Kirby-Bauer method. 90% of the strains showed varying ability to form biofilms. Biofilm-producing strains were categorized as strong (OD>1.7), moderate (OD between 0.862 and 1.7), weak (OD between 0.48 and 0.862) and null (OD<0.48). Frequencies were of 19.1%, 50%, 21.4% and 9.5% for strong, moderate, weak and null categories. Seven out of nine strong biofilm-producing strains showed antimicrobial susceptibility to all antibiotics tested. Heterogeneous antibiotic susceptibility was observed among moderate and weak biofilm-producing strains. Strains with null capacity showed resistance to two or more antibiotics and most of the NTHi isolates were able to form biofilms. Our results showed a high frequency of strains with moderate to strong biofilm-forming ability that were susceptible to most of the tested antimicrobial agents. Analysis of data concerning antimicrobial susceptibility and biofilm formation ability, may serve as a guide for surveillance and selection of antibiotic treatment in these patients.

Biography :

Patricia Gomez de Leon has completed her PhD from UNAM and two Postdoctoral Studies from Centers for Disease Control, USA, and CSIC/CIB, Madrid. She is a full Professor at the School of Medicine UNAM. She has published more than 28 papers in reputed journals and has been serving as an Editorial Board Member of recognized journals. She oversees evaluation and decisions of research designs for funding CONACYT, Mexico.